In an attempt to diversify its metabolic disease portfolio, Novo Nordisk has entered into a global collaboration and license agreement with Septerna to develop small molecules for obesity, type 2 diabetes and other cardiometabolic diseases. The deal, which is valued at up to US$2.2 B, will leverage Septerna’s Native Complex Platform to discover, develop and commercialise multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The deal marks yet another obesity-focused deal signed by Novo, as it attempts to maintain its strong presence in the field.